 iStockAnalyst (press release) | Abbvie, Inc: Pfizer Levoxyl Recall, Humira Provide Near-Term Upside iStockAnalyst (press release) Most of these products are in economically attractive specialty markets (e.g. Elotuzumab in multiple myeloma, and Daclizumab in multiple sclerosis). AbbVie, the R&D based pharmaceutical component of the former Abbott Labs (NYSE:ABT), is unique among ... |
